Sensei Biotherapeutics (NASDAQ:FTH) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Sensei Biotherapeutics (NASDAQ:FTH) from a sell rating to a hold rating in a report published on Saturday.

Several other research firms have also recently weighed in on FTH. HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Sensei Biotherapeutics in a report on Tuesday, August 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Sensei Biotherapeutics in a research report on Thursday, June 4th. JonesTrading initiated coverage on shares of Sensei Biotherapeutics in a research report on Tuesday, August 4th. They set a “buy” rating and a $55.00 target price on the stock. Weiss Ratings assumed coverage on shares of Sensei Biotherapeutics in a report on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. Finally, Needham & Company LLC initiated coverage on shares of Sensei Biotherapeutics in a research report on Friday. They issued a “buy” rating and a $56.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Sensei Biotherapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $55.00.

Sensei Biotherapeutics Stock Performance

NASDAQ FTH opened at $34.71 on Friday. The firm has a market cap of $896.91 million, a P/E ratio of -0.25 and a beta of -0.25. Sensei Biotherapeutics has a twelve month low of $7.45 and a twelve month high of $37.90. The firm’s fifty day moving average price is $27.42.

Sensei Biotherapeutics (NASDAQ:FTH) last issued its earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($5.04) by $2.20. Equities research analysts anticipate that Sensei Biotherapeutics will post -13.18 EPS for the current year.

Insider Buying and Selling at Sensei Biotherapeutics

In other news, major shareholder James Peyer sold 25,000 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $20.02, for a total value of $500,500.00. Following the completion of the sale, the insider owned 130,142 shares of the company’s stock, valued at approximately $2,605,442.84. This represents a 16.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Brian C. Stephenson acquired 5,000 shares of the stock in a transaction dated Wednesday, July 1st. The shares were bought at an average price of $23.50 per share, with a total value of $117,500.00. Following the completion of the transaction, the chief financial officer directly owned 46,688 shares of the company’s stock, valued at $1,097,168. The trade was a 11.99% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have purchased 49,494 shares of company stock worth $1,188,822. Insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in FTH. Vivo Capital LLC bought a new stake in shares of Sensei Biotherapeutics in the 1st quarter valued at $22,758,000. Alyeska Investment Group L.P. bought a new position in Sensei Biotherapeutics during the second quarter worth $3,610,000. Stempoint Capital LP acquired a new position in Sensei Biotherapeutics in the first quarter valued at $4,188,000. Bank of America Corp DE lifted its holdings in Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after buying an additional 32,719 shares during the period. Finally, Renaissance Technologies LLC boosted its position in Sensei Biotherapeutics by 178.2% during the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after acquiring an additional 20,525 shares during the last quarter. Institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.